Image pharmaphorum Editor Digital Underinvestment in medtech threatens sector growth - EY Underinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young (EY). News Public inquiry investigates thousands of deaths from infecte... A public inquiry has opened to look into how infected NHS blood killed more than 2,900 people since the 1970s. News FDA rejects Pharming's Ruconest HAE label expansion The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE). News Pharma depriving developing countries of taxes - report A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually. Load more results
Digital Underinvestment in medtech threatens sector growth - EY Underinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young (EY).
News Public inquiry investigates thousands of deaths from infecte... A public inquiry has opened to look into how infected NHS blood killed more than 2,900 people since the 1970s.
News FDA rejects Pharming's Ruconest HAE label expansion The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE).
News Pharma depriving developing countries of taxes - report A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
